Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CC-5013 (Celgene).

Constantine S Mitsiades1, Nicholas Mitsiades

  • 1Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|July 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma.

Blood·2026
Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026
Same author

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.

Cancer cell·2026
Same author

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

Blood·2026
Same author

Humanized Bone Model Identifies BMP6 as a Multifunctional Regulator in Myeloma Bone Disease.

Biomolecules·2025
Same author

Highly specific intracellular ubiquitination of a small molecule.

Nature chemical biology·2025

Celgene and the National Cancer Institute are developing CC-5013, a thalidomide derivative, to treat cancers and inflammatory diseases by inhibiting tumor necrosis factor-alpha (TNF-alpha) overproduction.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Tumor necrosis factor-alpha (TNF-alpha) is implicated in various cancers and inflammatory conditions.
  • Thalidomide derivatives offer a potential therapeutic avenue by modulating cytokine production.

Purpose of the Study:

  • To investigate the potential of CC-5013, a novel thalidomide derivative, as a therapeutic agent.
  • To evaluate the efficacy of CC-5013 in treating hematological and solid tumor cancers and inflammatory diseases.

Main Methods:

  • Development of CC-5013, a compound designed to inhibit TNF-alpha overproduction.
  • Preclinical and clinical investigations into the therapeutic effects of CC-5013.

Main Results:

  • CC-5013 demonstrates the ability to inhibit TNF-alpha overproduction.

Related Experiment Videos

  • The compound shows promise for the treatment of various cancer types and inflammatory disorders.

    • Conclusions:

    • CC-5013 represents a promising therapeutic candidate for oncological and inflammatory conditions.
    • Inhibition of TNF-alpha overproduction is a viable strategy for treating these diseases.